key: cord-0791444-7af6r6d1
authors: Qin, Xingyue; Huang, Chen; Wu, Ka; Li, Yu; Liang, Xiao; Su, Min; Li, Rong
title: Anti–coronavirus disease 2019 (COVID‐19) targets and mechanisms of puerarin
date: 2020-11-26
journal: J Cell Mol Med
DOI: 10.1111/jcmm.16117
sha: ea0f40c891dab815881d0f48e843212db89d36b1
doc_id: 791444
cord_uid: 7af6r6d1

The present study aimed to uncover the pharmacological function and underlying mechanism of puerarin as a potential treatment for COVID‐19, using an in silico methodology, including network pharmacology and molecular docking. The pivotal targets of puerarin to treat COVID‐19 were identified and included the epidermal growth factor receptor (EGFR), tumour necrosis factor (TNF), tumour protein p53 (TP53), caspase 3 (CASP3), RELA proto‐oncogene (RELA), Fos proto‐oncogene (FOS), caspase 8 (CASP8), prostaglandin‐endoperoxide synthase 2 (PTGS2), interleukin 2 (IL2), protein kinase CB (PRKCB), B cell lymphoma/leukaemia gene‐2 (BCL2), protein kinase CA (PRKCA), nitric oxide synthase 3 (NOS3) and peroxisome proliferator–activated receptor gamma (PPARG). Functionally, the anti–COVID‐19 action of puerarin was associated with the suppression of oxidative stress and inflammatory cascades, and cell apoptosis. The signalling pathways of puerarin to treat COVID‐19 included modulation of the pathways of apoptosis, IL‐17 signalling, mitogen‐activated protein kinase (MAPK) signalling and TNF signalling. Molecular docking data illustrated the binding capacity of puerarin with COVID‐19 and the effective anti–COVID‐19 activity of puerarin. Taken together, our current network pharmacology–based findings revealed the pharmacological role of puerarin in the treatment of COVID‐19. Furthermore, the bioinformatic findings elucidated that some of these pivotal targets might serve as potential molecular markers for detecting COVID‐19.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogenic agent responsible for causing COVID-19, a severe and life-threatening epidemic disease that has led to a massive economic burden and increasing death toll in the world. 1 As an evolving epidemic, COVID-19 is rapidly growing and spreading in several countries, including the United States, Brazil and India. 2 Epidemiological evidence suggests that the trend of COVID-19 infection is difficult to control because of insufficient management against COVID-19, characterized by huge rates of cases in different countries. 3 In the United States, COVID-19 has already affected millions of people and is characterized by an increasing incidence and death rate. 4 Pathologically, the main clinical characteristics of COVID-19 are related to inflammation, cytokine storms, immunodeficiency and infection. 5 In clinical management against COVID-19, the common therapy may involve supportive care, 6 such as breathing assistance, as the development of an effective drug and new vaccine is still ongoing. 7 Traditionally, Pueraria montana (Gegen) is found to relieve muscle fever, neutralize alcoholism-related hypoglycaemic and hypolipemic actions. 8 Puerarin, rich in Pueraria montana, exerts evident pharmacological benefits, such as preventing coronary heart disease and anti-alcoholism and anti-diabetic effects. 9 In our previous preclinical studies, puerarin was found to have potent hepatoprotection, neuroprotection and anti-dysmetabolism effects. [10] [11] [12] [13] It has been reported that puerarin may function as a natural amoebicidal agent to manage Acanthamoeba-induced pneumonia. 14 In addition, puerarin plays an important role in anti-inflammatory action, including prevention of acute lung injury by reducing inflammatory stress. 15, 16 However, there is currently no specific drug for the treatment of COVID-19. Although some antiviral drugs and traditional Chinese medicines have been used in the clinical treatment of COVID-19, its therapeutic effectiveness is not clear. Collectively, we aimed to determine and identify the curative effect of puerarin in the treatment of COVID-19 and the therapeutic mechanisms involved. It is of great interest to use bioinformatic and computational methods based on network pharmacology to unveil the potential agent to treat illness. 17 Using the network pharmacology strategy, we have reported the pharmacological targets and molecular pathways of bioactive agents against complex diseases. 18, 19 Thus, in this bioinformatic report, we intended to reveal the component-target-pathway network and pharmacological mechanism of puerarin in the treatment of COVID-19.

The total established target genes of puerarin were selected using the effective tools of traditional Chinese medicine systems pharmacology (TCMSP), Swiss Target Prediction and SuperPred.

Meanwhile, other COVID-19-nosopoietic genes were acquired using the gene-disease associations (DisGeNET) and GeneCards databases. Additionally, these acknowledged genes of puerarin and COVID-19 were mapped prior to emendation using the UniProt tool.

After functional enrichment analysis using FunRich software, all anti-COVID-19 biotargets of puerarin were screened and identified, as reported elsewhere. 20,21

The total acknowledged targets of puerarin and COVID-19 were used to further determine and construct a functional protein association network via the STRING database following a specific algorithm. In addition, these merged targets of puerarin and COVID-19 were used to construct a network of protein-protein interactions (PPI) using the Cytoscape software. As revealed by topological parameters using the Network Analyzer tool, the pivotal targets of puerarin to treat COVID-19 were identified and visualized. 22,23

Using the R language packages, such as 'ClusterProfiler', 'ReactomePA', 'org.Hs.eg.Db' and 'GOplot' in the R language 

Using the chemical-protein binding method, the pivotal targets were screened out and identified for puerarin-based molecular docking analysis. After searching for specific proteins through the PDB database, 5R84 protein was selected to dock with the puerarin compound. 

As revealed in Figure 1 , 393 COVID-19-morbid genes were selected and detected. A total of 138 putative genes of puerarin were specified following the databases. As shown in the Venn diagram, 34 shared genes of puerarin to treat COVID-19 were screened and identified. Furthermore, these mapped genes were reused to plot an interaction network.

All the mapped intersection proteins were input into Cytoscape 3. 

Following the assays using R language-related packages, the anti-COVID-19 molecular pathways from puerarin-achieved pivotal targets F I G U R E 1 All common genes of puerarin and COVID-19 were identified in a Venn map prior to further identification of the shared targets of puerarin to treat COVID-19. Total 34 shared targets of puerarin to treat COVID-19 were harvested and plotted for construction of a PPI network Figure 4A ,B, Table S3 ).

Further, the network visualization of puerarin-target-biological process (BP)-KEGG-COVID-19 was created using Cytoscape 3.7.1 software, as shown in Figure 5 .

In details, an integrated network map from pivotal targets was plotted and revealed the intersection association of targetdisease-function-pathway in puerarin to treat COVID-19 

In our current study, the in silico findings from the network phar- also related to apoptotic cell death. 28 Prostaglandin-endoperoxide F I G U R E 6 Molecular docking findings suggested that the binding capacity of puerarin against COVID-19 was significant in the pivotal target/protein. The biostructural original ligands binding to targeting protein with effective docking energy, as shown in A and B synthase (PTGS) is responsible for the prostanoid biosynthesis involved in inflammation and mitogenesis when it is induced by specific stimulatory genes. 29 Some interesting data indicate that targeting suppression of PGE2 synthesis is likely to reduce bacterial infection in mice. 30 Protein kinase C (PKC), including PRKCB and PRKCA, is involved in diverse cellular signalling pathways, including those involved in cancer. 31 The proteins encoded by PRKCB and PRKCA genes have been reported to be associated with numerous cellular functions, such as B cell activation, apoptosis induction and endothelial cell proliferation. 32 NOS3 (nitric oxide synthase 3) may induce nitric oxide release for the regulation of angiogenesis and cell proliferation. 33 Interestingly, NOS3 may functionally suppress sepsis-caused systemic inflammation and myocardial dysfunction in mice. 34 Collectively, there is no associated investigation for the associations between FOS, PTGS, PRKCB, PRKCA, NOS3 and COVID-19.

Therefore, the current in silico findings using network pharmacology uncovered all pharmacological targets, functions and signalling pathways of puerarin to treat COVID-19, marked by inhibition of cytonecrosis-and inflammation-associated signalling pathways, such as the IL-17 signalling pathway, TNF signalling pathway, MAPK signalling pathway and HIF-1 signalling pathway. Potentially, puerarin may be a promising active compound against COVID-19. However, it needs to be confirmed by future experimental works.

In silico approaches based on network pharmacology and molecular docking were used to harvest the mapped and pivotal biotargets, 

The data that supports the findings of this study are available in the supplementary material of this article.

https://orcid.org/0000-0002-7867-1539

Rong Li https://orcid.org/0000-0002-8210-1213

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

The outbreak of COVID-19: an overview

Understanding of COVID-19 based on current evidence

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): early report from the United States

Epidemiology and clinical characteristics of COVID-19

Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity

Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status

Pueraria lobata for diabetes mellitus: past, present and future

Puerarin: a review of pharmacological effects

Puerarin mediates hepatoprotection against CCl4-induced hepatic fibrosis rats through attenuation of inflammation response and amelioration of metabolic function

Puerarin attenuates neuronal degeneration and blocks oxidative stress to elicit a neuroprotective effect on substantia nigra injury in 6-OHDA-lesioned rats

Puerarin attenuates neuronal degeneration in the substantia nigra of 6-OHDA-lesioned rats through regulating BDNF expression and activating the Nrf2/ ARE signaling pathway

Puerarin exerts the protective effect against chemical induced dysmetabolism in rats

Plant extracts as natural amoebicidal agents

Puerarin prevents LPS-induced acute lung injury via inhibiting inflammatory response

Protective effects of puerarin on acute lung and cerebrum injury induced by hypobaric hypoxia via the regulation of aquaporin (AQP) via NF-κB signaling pathway

Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: a study of network pharmacology

To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis

Bioinformatic and experimental data decipher the pharmacological targets and mechanisms of plumbagin against hepatocellular carcinoma

Therapeutic target and molecular mechanism of vitamin C-treated pneumonia: a systematic study of network pharmacology

Revealing the targets and mechanisms of vitamin A in the treatment of COVID-19

Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: analyses of network pharmacology, human and experimental data

Pharmacological targets and molecular mechanisms of plumbagin to treat colorectal cancer: a systematic pharmacology study

Therapeutic targets and signaling mechanisms of Vitamin C activity against sepsis: a bioinformatics study

Integrative pharmacological mechanism of vitamin C combined with glycyrrhizic acid against COVID-19: findings of bioinformatics analyses

Pharmacological targets and mechanisms of calycosin against meningitis

Functional benefit and molecular mechanism of vitamin C against perfluorooctanesulfonate-associated leukemia

The Fos family of transcription factors and their role in tumourigenesis

Prostaglandin synthases: molecular characterization and involvement in prostaglandin biosynthesis

Increased lethality and defective pulmonary clearance of Streptococcus pneumoniae in microsomal prostaglandin E synthase-1-knockout mice

Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression

Deciphering the role of protein kinase D1 (PKD1) in cellular proliferation

nNOS deficiency-induced cell proliferation depletes the neurogenic reserve

Nos3 protects against systemic inflammation and myocardial dysfunction in murine polymicrobial sepsis